184 related articles for article (PubMed ID: 20214543)
1. Effect of control selection on sustained viral response rates in genotype 2/3 HCV mono-infected versus HIV/HCV co-infected patients.
Nilsson J; Weiland O
Scand J Infect Dis; 2010 Jul; 42(6-7):533-9. PubMed ID: 20214543
[TBL] [Abstract][Full Text] [Related]
2. Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals.
Shea DO; Tuite H; Farrell G; Codd M; Mulcahy F; Norris S; Bergin C
J Viral Hepat; 2008 Jul; 15(7):482-9. PubMed ID: 18221297
[TBL] [Abstract][Full Text] [Related]
3. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
[TBL] [Abstract][Full Text] [Related]
4. Plasma HCV-RNA decline in the first 48 h identifies hepatitis C virus mono-infected but not HCV/HIV-coinfected patients with an undetectable HCV viral load at week 4 of peginterferon-alfa-2a/ribavirin therapy.
Arends JE; Stuart JC; Baak LC; van der Ende ME; van Erpecum KJ; Simons CP; Boland GJ; van Baarle D; Hoepelman AI
J Viral Hepat; 2009 Dec; 16(12):867-75. PubMed ID: 19457139
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
[TBL] [Abstract][Full Text] [Related]
6. HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia.
Shire NJ; Horn PS; Rouster SD; Stanford S; Eyster ME; Sherman KE;
Hepatology; 2006 Nov; 44(5):1146-57. PubMed ID: 17058240
[TBL] [Abstract][Full Text] [Related]
7. Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy.
Rivero-Juarez A; Neukam K; Labarga P; Camacho A; Macias J; Barreiro P; Torre-Cisneros J; Pineda JA; Soriano V; Rivero A
J Infect; 2014 Apr; 68(4):372-7. PubMed ID: 24269677
[TBL] [Abstract][Full Text] [Related]
8. Treatment of hepatitis C in patients with haemophilia - the Israeli National Hemophilia Center experience.
Maor Y; Schapiro JM; Bashari D; Lurie Y; Safadi R; Segol O; Paritsky M; Rachlis Z; Avidan B; Bar-Meir S; Martinowitz U
Haemophilia; 2008 Mar; 14(2):336-42. PubMed ID: 18205802
[TBL] [Abstract][Full Text] [Related]
9. HCV RNA decline in chronic HCV genotype 2 and 3 during standard of care treatment according to IL28B polymorphism.
Stenkvist J; Sönnerborg A; Weiland O
J Viral Hepat; 2013 Mar; 20(3):193-9. PubMed ID: 23383658
[TBL] [Abstract][Full Text] [Related]
10. IP-10 predicts the first phase decline of HCV RNA and overall viral response to therapy in patients co-infected with chronic hepatitis C virus infection and HIV.
Falconer K; Askarieh G; Weis N; Hellstrand K; Alaeus A; Lagging M
Scand J Infect Dis; 2010 Dec; 42(11-12):896-901. PubMed ID: 20608766
[TBL] [Abstract][Full Text] [Related]
11. Management of hepatitis C in HIV infected and other immunocompromised individuals.
Seth AK
Trop Gastroenterol; 2006; 27(3):111-7. PubMed ID: 17310553
[TBL] [Abstract][Full Text] [Related]
12. The GNB3 C825T polymorphism affects response to HCV therapy with pegylated interferon in HCV/HIV co-infected but not in HCV mono-infected patients.
Ahlenstiel G; Nischalke HD; Bueren K; Berg T; Vogel M; Biermer M; Grünhage F; Sauerbruch T; Rockstroh J; Spengler U; Nattermann J
J Hepatol; 2007 Sep; 47(3):348-55. PubMed ID: 17559964
[TBL] [Abstract][Full Text] [Related]
13. LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients.
Rivero-Juarez A; Camacho A; Caruz A; Neukam K; Gonzalez R; Di Lello FA; Perez-Camacho I; Mesa P; Torre-Cisneros J; Peña J; Pineda JA; Rivero A
AIDS; 2012 May; 26(8):1009-15. PubMed ID: 22382144
[TBL] [Abstract][Full Text] [Related]
14. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients.
Sherman KE; Shire NJ; Rouster SD; Peters MG; James Koziel M; Chung RT; Horn PS
Gastroenterology; 2005 Feb; 128(2):313-27. PubMed ID: 15685543
[TBL] [Abstract][Full Text] [Related]
15. Peginterferon-alfa mono-therapy in the treatment of acute hepatitis C in HIV-infection.
Boesecke C; van Assen S; Stellbrink HJ; Baumgarten A; Ingiliz P; Strassburg CP; Schwarze-Zander C; Wasmuth JC; Hoepelman AI; Rockstroh JK; Arends JE
J Viral Hepat; 2014 Nov; 21(11):780-5. PubMed ID: 25040149
[TBL] [Abstract][Full Text] [Related]
16. Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: the HEPAIG study.
Piroth L; Larsen C; Binquet C; Alric L; Auperin I; Chaix ML; Dominguez S; Duval X; Gervais A; Ghosn J; Delarocque-Astagneau E; Pol S;
Hepatology; 2010 Dec; 52(6):1915-21. PubMed ID: 21064156
[TBL] [Abstract][Full Text] [Related]
17. Evaluation and treatment of hepatitis C in patients with human immunodeficiency virus.
Bakaj G; Valasiuk T; Prabhukhot R; Siraj D
South Med J; 2012 Oct; 105(10):500-3. PubMed ID: 23038477
[TBL] [Abstract][Full Text] [Related]
18. HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
Bruno G; Saracino A; Scudeller L; Fabrizio C; Dell'Acqua R; Milano E; Milella M; Ladisa N; Monno L; Angarano G
Int J Infect Dis; 2017 Sep; 62():64-71. PubMed ID: 28728927
[TBL] [Abstract][Full Text] [Related]
19. [A preliminary assessment of the clinical utility of measuring hepatitis C virus antibody to evaluate infection status].
Long L; Liu Y; Duan Z; Xu Q; Shen T; Dou X; Zhuang H; Lu F
Zhonghua Gan Zang Bing Za Zhi; 2014 Apr; 22(4):244-50. PubMed ID: 25173220
[TBL] [Abstract][Full Text] [Related]
20. Immune biomarker differences and changes comparing HCV mono-infected, HIV/HCV co-infected, and HCV spontaneously cleared patients.
Kushner LE; Wendelboe AM; Lazzeroni LC; Chary A; Winters MA; Osinusi A; Kottilil S; Polis MA; Holodniy M
PLoS One; 2013; 8(4):e60387. PubMed ID: 23593207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
